期刊
FRONTIERS OF MEDICINE
卷 9, 期 2, 页码 173-186出版社
SPRINGER
DOI: 10.1007/s11684-015-0384-0
关键词
metformin; diabetes; hepatic steatosis; inflammatory response; insulin resistance
资金
- National Natural Science Foundation of China [81100562/H0711]
- National Key Basic Research Program of China [2012CB910402]
- ADA [1-13-BS-214-BR]
- AHA [12BGIA9050003]
- NIH/NIDDK [1R01DK095828, 1R01DK095862]
Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of type 2 diabetes (T2D). As a drug that primarily targets the liver, metformin suppresses hepatic glucose production (HGP), serving as the main mechanism by which metformin improves hyperglycemia of T2D. Biochemically, metformin suppresses gluconeogenesis and stimulates glycolysis. Metformin also inhibits glycogenolysis, which is a pathway that critically contributes to elevated HGP. While generating beneficial effects on hyperglycemia, metformin also improves insulin resistance and corrects dyslipidemia in patients with T2D. These beneficial effects of metformin implicate a role for metformin in managing non-alcoholic fatty liver disease. As supported by the results from both human and animal studies, metformin improves hepatic steatosis and suppresses liver inflammation. Mechanistically, the beneficial effects of metformin on hepatic aspects are mediated through both adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. In addition, metformin is generally safe and may also benefit patients with other chronic liver diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据